Triple Negative Breast Neoplasms
-
Subject Areas on Research
- A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models.
- A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
- Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence.
- An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.
- An unexpected alliance between stress responses to drive oncogenesis.
- Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
- Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy.
- Breast cancer subtypes and previously established genetic risk factors: a bayesian approach.
- CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.
- Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
- Circulating tumor cell analysis in metastatic triple-negative breast cancers.
- Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
- Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.
- Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.
- Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism.
- Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
- Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.
- Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.
- Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?
- MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
- MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
- MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
- Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis.
- Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
- Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
- Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
- Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
- Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
- Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
- Post-irradiation morphoea of the breast: a case report and review of the literature.
- Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
- Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
- Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.
- Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).
- Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy.
- Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status.
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
- Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
- The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer.
- The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors.
- The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.
- αB-crystallin: a novel regulator of breast cancer metastasis to the brain.